Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy.
CFTR modulator
cystic fibrosis
elexacaftor
ivacaftor
tezacaftor
Journal
The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
ISSN: 1551-6776
Titre abrégé: J Pediatr Pharmacol Ther
Pays: United States
ID NLM: 101089851
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
9
4
2020
pubmed:
9
4
2020
medline:
9
4
2020
Statut:
ppublish
Résumé
Elexacaftor-tezacaftor-ivacaftor is a newly approved triple-combination cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapy that contains 2 correctors and a potentiator of the CFTR channel. Its labeled indication for use is for persons 12 years of age and older with at least 1 F508del mutation for the
Identifiants
pubmed: 32265602
doi: 10.5863/1551-6776-25.3.192
pmc: PMC7134581
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
192-197Informations de copyright
Copyright Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2020.
Déclaration de conflit d'intérêts
Disclosure The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria.
Références
Curr Opin Pediatr. 2018 Jun;30(3):372-377
pubmed: 29538046
Lancet. 2016 Nov 19;388(10059):2519-2531
pubmed: 27140670
Lancet. 2019 Nov 23;394(10212):1940-1948
pubmed: 31679946
Ann Am Thorac Soc. 2018 Mar;15(3):271-280
pubmed: 29342367
N Engl J Med. 2019 Nov 7;381(19):1809-1819
pubmed: 31697873